Moderna's $320M Trading Volume Ranks 375th as CEO Outlines Strategic Update on Respiratory Vaccines and Oncology Expansion

On September 8, 2025, , ranking 375th in market activity. , reflecting investor sentiment ahead of its strategic update at the Morgan Stanley healthcare conference.

During the conference, CEO outlined Moderna’s focus on respiratory vaccines, oncology, and international expansion. , . Recent approvals for three , including two COVID-19 variants, underscore its progress in respiratory disease. post-pandemic and partnerships like the flu phase 3 study with Blackstone are highlighted as growth drivers.

Moderna’s respiratory portfolio, including RSV and flu-COVID combo vaccines, is positioned to capture market share, particularly in international markets like the UK and Canada. The company also emphasized its oncology pipeline, notably the Individualized Neoantigen Therapy (INT) collaboration with Merck, and plans to file for flu and combo vaccines by year-end. Policy shifts allowing pharmacists to administer vaccines independently are expected to ease distribution bottlenecks in key states.

To give you a precise, tradable back-test I need to pin down a few implementation details: 1. Market universe • All U.S. listed common stocks, or a smaller universe (e.g., S&P 1500 constituents)? 2. Ranking & timing convention • Rank by today’s total dollar volume or share turnover? • Buy at today’s close and liquidate at tomorrow’s close, or open-to-open, etc.? 3. Position sizing • Equal-weight the 500 names each day? (Default) • Any cash drag restrictions or leverage? 4. Costs / slippage • Include commissions or a bps spread estimate, or ignore for this run? (Default: ignore) 5. Risk controls • Stop-loss, max drawdown, etc., or none? (Default: none for this 1-day-hold test) Once I have these clarified I can generate the data-retrieval plan and run the back-test.